Skip to main content
Premium Trial:

Request an Annual Quote

APB to Proceed with IPO Despite Market Conditions, ABI Warning

NEW YORK, March 22 – Nycomed Amersham is continuing with its plans to launch an initial public offering of shares in its subsidiary Amersham Pharmacia Biotech on the Nasdaq this spring, despite the downturn in the economy and a warning from competitor Applied Biosystems, the company said Thursday.

“As far as the IPO goes, we continue to work through the normal process with the SEC in filing our registration statement,” Tracy Cheung, vice president of investor relations at AP Biotech, told GenomeWeb.

The company is planning to sell 18.2 million shares, or 10 percent of the company's equity, at between $15 and $17 a share. Cheung noted, however, that the pricing structure could change as could the company's plans for the IPO, adding that the final decision would be “subject to market conditions.”

Amersham's comments follow Wednesday’s announcement from AP Biotech competitor Applied Biosystems that its short-term growth would be slowed by drop-offs in orders from customers for its instruments due to the downturn in the economy.

Michael Hunkapiller, president of Applied Biosystems, said the company’s short-term growth rate would be one half to two-thirds of its expected long-term growth rate of 20 percent.

The effects of the announcement reverberated on Wall Street Thursday. Applied Biosystems' shares were down a sharp 45 percent, at $18.80 in late morning trading, compared with Wednesday's close of $34.45. Nycomed Amersham’s shares had also dropped over 10 percent to $30.25, down from Wednesday's close of $33.75. 

Cheung said, however, that AP Biotech’s short-term forecast still looked strong.

“We did say at the end of February that AP Biotech had made a good start for the year and that we should continue to see the benefits, partly as results of delayed sales from December, and that we should also see the benefits of new product launches this quarter," she said.   

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.